FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy December 15, 2021 21:45 CET Non Regulatory Read more
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 November 3, 2021 08:00 CET Non Regulatory Read more
Calliditas announces acquisition of remaining Genkyotex minority shares October 7, 2021 08:00 CET Non Regulatory Read more
Calliditas Receives FDA Fast Track Designation for setanaxib in PBC August 9, 2021 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference May 28, 2021 12:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 May 14, 2021 14:00 CET Non Regulatory Read more
Calliditas promotes Andrew Udell to President, North America May 3, 2021 14:30 CET Non Regulatory Read more
Calliditas strengthens its US Commercial and Medical Affairs Organization March 8, 2021 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice March 4, 2021 14:30 CET Non Regulatory Read more
First Patient Dosed in NefIgArd Open Label Extension Study February 4, 2021 08:30 CET Non Regulatory Read more
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial January 21, 2021 08:30 CET Non Regulatory Read more
Positive Phase 1 results in high-dose setanaxib trial January 18, 2021 08:00 CET Non Regulatory Read more
Agenda for Calliditas virtual R&D Day on January 20, 2021 January 15, 2021 09:00 CET Non Regulatory Read more